Warning: The NCBI web site requires JavaScript to function. more...
Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members.
Olayioye MA.
Breast Cancer Res. 2001;3(6):385-9. Epub 2001 Oct 4. Review.
Related citations
Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.
Nagy P, Jenei A, Damjanovich S, Jovin TM, Szölôsi J.
Pathol Oncol Res. 1999;5(4):255-71. Review.
Dysregulation of cellular signaling by HER2/neu in breast cancer.
Zhou BP, Hung MC.
Semin Oncol. 2003 Oct;30(5 Suppl 16):38-48. Review.
Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.
Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW.
Semin Oncol. 2002 Jun;29(3 Suppl 11):11-21. Review.
Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment.
Hurst HC.
Breast Cancer Res. 2001;3(6):395-8. Epub 2001 Oct 1. Review.
The ErbB2 signaling network as a target for breast cancer therapy.
Badache A, Gonçalves A.
J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):13-25. Review.
The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention.
Citri A, Kochupurakkal BS, Yarden Y.
Cell Cycle. 2004 Jan;3(1):51-60. Review.
HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.
Ahmed KM, Cao N, Li JJ.
Anticancer Res. 2006 Nov-Dec;26(6B):4235-43. Review.
HER-2 signaling and inhibition in breast cancer.
Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N.
Curr Cancer Drug Targets. 2009 May;9(3):419-38. Review.
Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW, Kim MR, Kim HG, Kim SK, Jeong HG, Kang KW.
Arch Pharm Res. 2008 Mar;31(3):350-6. Epub 2008 Apr 13.
Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
Meric-Bernstam F, Hung MC.
Clin Cancer Res. 2006 Nov 1;12(21):6326-30. Review.
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R.
Int J Mol Med. 2007 Jul;20(1):3-10. Review.
Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.
Nagy P, Vereb G, Sebestyén Z, Horváth G, Lockett SJ, Damjanovich S, Park JW, Jovin TM, Szöllosi J.
J Cell Sci. 2002 Nov 15;115(Pt 22):4251-62.
ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
Stern DF.
J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):215-23. Epub 2008 May 3. Review.
Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L, Xiang B, Muthuswamy SK.
Cancer Res. 2006 May 15;66(10):5201-8.
Targeting the HER-kinase axis in cancer.
Gross ME, Shazer RL, Agus DB.
Semin Oncol. 2004 Feb;31(1 Suppl 3):9-20. Review.
Receptor-targeted cancer therapy.
Richter M, Zhang H.
DNA Cell Biol. 2005 May;24(5):271-82. Review.
Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
Bedard PL, de Azambuja E, Cardoso F.
Curr Cancer Drug Targets. 2009 Mar;9(2):148-62. Review.
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.
Arteaga CL, Moulder SL, Yakes FM.
Semin Oncol. 2002 Jun;29(3 Suppl 11):4-10. Review.
Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.
Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S, Lucini F, Ingvarsson S, Segatto O.
Oncogene. 2005 Jun 30;24(28):4540-8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on